Медицинская литература. Новинки

 

 

 

 

 

 

Система LI-RADS при компьютернотомографической диагностике гепатоцеллюлярного рака

Вы можете загрузить полный текст статьи в формате pdf

Представлены данные литературы по компьютернотомографическим характеристикам гепатоцеллюлярного рака. Проведен критический анализ критериев дифференциальной диагностики системы LI-RADS и показателей эффективности локорегионального лечения системы mRECIST Показано, что эффективность выявления и верификации гепатоцеллюлярного рака зависит прежде всего от размеров образования и состояния окружающей ткани печени. В основе изменений компьютерно-томографической семиотики гепатоцеллюлярного рака на разных фазах сканирования лежат особенности его кровоснабжения.

Ключевые слова:
гепатоцеллюлярный рак, компьютерная томография, LI-RADS, mRECIST, hepatocellular carcinoma, computed tomography, LI-RADS, mRECIST

Литература:
1.Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J. Clin. 2014; 64 (1): 9-29.
2.Состояние онкологической помощи населению России в 2013 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ МНИОИ им. П.А. Герцена Минздрава России, 2014. 235 с.
3.Trevisani F., Frigerio M., Santi V. et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig. Liver Dis. 2010; 42 (5): 341-347.
4.Silva A.C., Evans J.M., McCullough A.E. et al. MR Imaging of hypervascular liver masses: A review of current techniques. Radiographics. 2009; 29 (2): 385-402.
5.Gaddikeri S., McNeeley M.F., Wang C.L. et al. Hepatocellular carcinoma in the noncirrhotic live. Am. J. Roentgenol. 2014; 203 (1): W34-47.
6.American College of Radiology. Quality and safety resources: Liver Imaging-Reporting and Data System. Available at: http://www.acr.org/QualitySafety/Resources/ LIRADS. Accessed April 22, 2012.
7.Willatt J.M., Hussain H.K., Adusumilli S., Marrero J.A. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008; 247 (2): 311-330.
8.Sharma P., Kalb B., Kitajima H.D. et al. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging. J. Magn. Reson. Imaging. 2011; 33 (1): 110-118.
9.Туманова У.Н., Кармазановский Г.Г., Щёголев А.И. Компьютерно-томографические характеристики степени васкуляризации гепатоцеллюлярного рака. Медицинская визуализация. 2013; 1: 52-58.
10.Yu J.S., Kim K.W., Sung K.B. et al. Small arterial-portal venous shunts: A cause of pseudolesions at hepatic imaging. Radiology. 1997; 203 (3): 737-742.
11.Yu J.S., Lee J.H., Chung J.J. et al. Small hypervascular hepatocellular carcinoma: Limited value of portal and delayed phases on dynamic magnetic resonance imaging. Acta Radiol. 2008; 49 (7): 735-743.
12.Brancatelli G., Federle M.P., Blachar A., Grazioli L. Hemangioma in the cirrhotic liver: Diagnosis and natural history. Radiology 2001; 219 (1): 69-74.
13.Туманова У.Н., Кармазановский Г.Г., Дубова Е.А., Щеголев А.И. Сравнительный анализ степени васкуляризации гепатоцеллюлярного рака и очаговой узловой гиперплазии печени по данным компьютерно-томографического и морфологического исследований. Вестник Российской Академии медицинских наук. 2013; 12: 9-15.
14.Marrero J.A., Hussain H.K., Nghiem H.V. et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005; 11 (3): 281-289.
15.Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am. J. Gastroenterol. 2010; 105 (3): 610-612.
16.Туманова У.Н., Дубова Е.А., Кармазановский Г.Г., Щёголев А.И. Компьютерная томография в оценке кровоснабжения гепатоцеллюлярного рака. Анналы хирургической гепатологии. 2013; 18 (4): 53-60.
17.Fowler K.J., Brown J.J., Narra V.R. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology. 2011; 54 (6): 2227-2237.
18.Туманова У.Н., Кармазановский Г.Г., Щеголев А.И. Денситометрические характеристики гепатоцеллюлярного рака при спиральной компьютерной томографии. Медицинская визуализация. 2012; 6: 42-50.
19.Jeong Y.Y., Mitchell D.G., Kamishima T Small (20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am. J. Roentgenol. 2002; 178 (6): 1327-1334.
20.Ueda K., Matsui O., Kawamori Y. et al. Hyper-vascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology. 1998; 206 (1): 161-166.
21.Sakata J., Shirai Y., Wakai T. et al. Preoperative predictors of vas-cular invasion in hepatocellular carcinoma. Eur. J. Surg. Oncol. 2008; 34 (8): 900-905.
22.Dodd G.D. 3rd, Memel D.S., Baron R.L. et al. Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? Am. J. Roentgenol. 1995; 165 (3): 573-577.
23.Ishigami K., Yoshimitsu K., Nishihara Y. et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium enhanced MR images: correlation with histopathologic findings. Radiology. 2009; 250 (2): 435-443.
24.Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42 (5): 1208-1236.
25.Lee J.M., Trevisani F., Vilgrain V., Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl. 2011; 17 (Suppl. 2): S34-43.
26.Yu J.S., Kim K.W., Jeong M.G. et al. Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology. 2000; 217 (3): 750-756.
27.Brancatelli G., Baron R.L., Peterson M.S., Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. Am. J. Roentgenol. 2003; 180 (4): 1007-1014.
28.Colagrande S., Centi N., Galdiero R., Ragozzino A. Transient hepatic intensity differences. 1. Those associated with focal lesions. Am. J. Roentgenol. 2007; 188 (1): 154-159.
29.Holland A.E., Hecht E.M., Hahn W.Y. et al. Importance of small ( or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology. 2005; 237 (3): 938-944.
30.Hwang S.H., Yu J.S., Kim K.W. et al. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J. Comput. Assist. Tomogr. 2008; 32 (1): 39-45.
31.Hussain S.M., Reinhold C., Mitchell D.G. Cirrhosis and lesion characterization at MR imaging. Radiographics. 2009; 29 (6): 1637-1652.
32.Bruix J., Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3): 1020-1022.
33.Marrero J.A., Hussain H.K., Nghiem H.V. et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005; 11 (3): 281-289.
34.Kim S.H., Choi B.I., Lee J.Y. et al. Diagnostic accuracy of multi-single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology. 2008; 51 (Suppl. 1): 52-60.
35.Dhanasekaran R., Limaye A., Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutic. Hepatic Medicine: Evidence and Research. 2012; 4: 19-37.
36.Krinsky G.A., Lee V.S., Theise N.D. et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: Prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001; 219 (2): 445-454.
37.Taouli B., Losada M., Holland A., Krinsky G. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology. 2004; 127 (5 Suppl. 1): S144-S152.
38.Bruix J., Sherman M., Llovet J.M. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35 (3): 421-430.
39.Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: An Eastern point of view. Liver Transpl. 2004; 10 (2 Suppl. 1): S3-S8.
40.Byrnes V., Shi H., Kiryu S. et al. The clinical outcome of small (20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am. J. Gastroenterol. 2007; 102 (8): 1654-1659.
41.Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92 (3): 205-216.
42.Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010: 30 (1): 52-60.

LI-RADS System for Computer-Tomographic Diagnosis of Hepatocellular Carcinoma

We have presented data from the literature on computed-tomographic characteristics of hepatocellular cancer Was carried out a critical analysis of the criteria for the differential diagnosis of the system LI-RADS and performance of locoregional treatment system mRECIST It is shown that the efficiency of detection and verification of hepatocellular cancer depends primarily on the dimensions of formation and the state of the liver tissue. In the basis of changes in computer-tomographic semiotics of hepatocellular cancer at different phases of the scan are features of its blood supply.

Keywords:
гепатоцеллюлярный рак, компьютерная томография, LI-RADS, mRECIST, hepatocellular carcinoma, computed tomography, LI-RADS, mRECIST